Trauth, B.C. and Klas, C. and Peters, A.M. and Matzku, S. and Möller, P. and Falk, Werner and Debatin, K.M. and Krammer, P.H.
Monoclonal antibody-mediated tumor regression by induction of apoptosis.
Science (New York, N.Y.) 245 (4915), pp. 301-305.
To characterize cell surface molecules involved in control of growth of malignant lymphocytes, monoclonal antibodies were raised against the human B lymphoblast cell line SKW6.4. One monoclonal antibody, anti-APO-1, reacted with a 52-kilodalton antigen (APO-1) on a set of activated human lymphocytes, on malignant human lymphocyte lines, and on some patient-derived leukemic cells. Nanogram quantities of anti-APO-1 completely blocked proliferation of cells bearing APO-1 in vitro in a manner characteristic of a process called programmed cell death or apoptosis. Cell death was preceded by changes in cell morphology and fragmentation of DNA. This process was distinct from antibody- and complement-dependent cell lysis and was mediated by the antibody alone. A single intravenous injection of anti-APO-1 into nu/nu mice carrying a xenotransplant of a human B cell tumor induced regression of this tumor within a few days. Histological thin sections of the regressing tumor showed that anti-APO-1 was able to induce apoptosis in vivo. Thus, induction of apoptosis as a consequence of a signal mediated through cell surface molecules like APO-1 may be a useful therapeutic approach in treatment of malignancy.
|Institutions:|| Medicine > Lehrstuhl für Innere Medizin I|
|Antibodies, Monoclonal/therapeutic use||MESH|
|Electrophoresis, Polyacrylamide Gel||MESH|
|Tumor Cells, Cultured||MESH|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||08 Sep 2010 05:25|
|Last Modified:||20 Jul 2011 22:34|